APA (7th ed.) Citation

Weichenthal, M., Debus, D., Zimmer, L., Wasielewski, I. v., Meier, F., Tüting, T., . . . Utikal, J. (2026). COMBI-EU: Real-world evidence on adverse event management and time on therapy with adjuvant dabrafenib plus trametinib in patients with BRAF V600-mutant melanoma. Cancers, 18(4), . https://doi.org/10.3390/cancers18040667

Chicago Style (17th ed.) Citation

Weichenthal, Michael, Dirk Debus, Lisa Zimmer, Imke von Wasielewski, Friedegund Meier, Thomas Tüting, Johannes Wohlrab, and Jochen Utikal. "COMBI-EU: Real-world Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-mutant Melanoma." Cancers 18, no. 4 (2026). https://doi.org/10.3390/cancers18040667.

MLA (9th ed.) Citation

Weichenthal, Michael, et al. "COMBI-EU: Real-world Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-mutant Melanoma." Cancers, vol. 18, no. 4, 2026, https://doi.org/10.3390/cancers18040667.